Researchers Discover Why Beta Blockers Lead to Inflammation
Inflammation from beta blockers is caused by a cellular process known as autophagy.
Related Articles
FDA Approves Guselkumab for Treatment of Ulcerative Colitis
Guselkumab (Tremfya; Johnson & Johnson) is the first and only approved fully human and dual-acting monoclonal antibody blocking interleukin-23 and binding to CD64 receptors.
Increased Psychological, Cardiovascular Risks in Relatives of Patients With Cancer
Parents of children with cancer had the highest risk of developing mental illness and cardiovascular diseases.
Non-Medical Switch to Infliximab Biosimilar Demonstrates Similar Outcomes for IBD
Investigators obtained real-world evidence to evaluate the clinical outcomes of non-medical switching from the infliximab (Remicade; Janssen Immunology) to a biosimilar.
Treatment Considerations for Patients With Small Cell Lung Cancer, Pre-Existing Interstitial Lung Disease
An overview of the potential treatment strategies for patients were presented at the 2024 World Conference on Lung Cancer.
HIV Infections Significantly Reduced With Twice-Yearly Lenacapavir in Cisgender Men, Gender-Diverse Participants
These results build off the PURPOSE 1 trial, contributing to the wealth of evidence surrounding lenacapavir’s positive effects in patients with HIV.
Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC
As of May 2024, follow-up and exploratory analyses of MARIPOSA show improvements in outcomes for patients with EGRF-mutated non–small cell lung cancer (NSCLC).
From Opioids to Cannabis: The Impact of Cannabis Rescheduling on Pharmacy Revenue Streams
The DEA will have a hearing in December 2024 regarding the potential reclassification of cannabis to Schedule III, which could significantly impact the regulatory environment…
Cutting-Edge Targeted, Cytotoxic, and Immunologic Therapies Form Next Generation of mNSCLC Treatments
Highlights from multiple trials investigating novel treatments for mNSCLC were presented at 2024 World Conference on Lung Cancer.
Advances With Various Therapies Targeting DLL3 in Lung Neuroendocrine Tumors
An overview of the latest developments in targeting DLL3 in lung neuroendocrine tumors were presented at the 2024 World Conference on Lung Cancer.
Local Therapy Developments Hold Promise for Survival Improvements for NSCLC
In a session at the 2024 World Conference on Lung Cancer, presenters highlight the most significant developments in local therapy for metastatic non–small cell lung…